EVX-01 personalized cancer vaccine moves into focus as Evaxion examines broader immune responses
Evaxion advances EVX-01 melanoma vaccine research with new Phase 2 immune biomarker data. Explore its 75% response rate and future potential.
Pharma & Biotech
Pharma & Biotech
PAS-004 advances toward Phase 2 as Pasithea seeks new treatment approach for cutaneous neurofibromas
Pasithea Therapeutics secures FDA clearance for PAS-004 Phase 2 testing in NF1 skin tumors. Explore the treatment potential and trial plans.
Pharma & Biotech
T-Cypher Bio reports promising cancer cell killing with two next-generation T-cell engagers.
T-Cypher Bio reports promising TC25 and TC11 cancer immunotherapy data. Find out how its T-cell engagers could reshape solid tumor treatment.
Pharma & Biotech
Trastuzumab pamirtecan slows breast cancer progression but raises interstitial lung disease concerns
BioNTech's breast cancer drug meets its Phase 3 endpoint but serious lung toxicity raises concerns. Explore the results and approval outlook.
Pharma & Biotech
Guardian Pharmacy Services has made another Tennessee acquisition, but can its local-first model sustain national growth?
Guardian Pharmacy Services has acquired Van's Institutional Pharmacy, adding a fifth Tennessee location to its long-term care pharmacy network while retaining the acquired business's local leadership and brand. The transaction extends its regional coverage, although the purchase price and financial contribution remain undisclosed.
Pharma & Biotech
Aarvik Therapeutics advances ARR-002 into Phase 1 and licenses two ADC candidates to Laurus Labs for India
Aarvik Therapeutics has reached its first human clinical milestone through ArriVent Biopharma's ARR-002 study and signed a separate India-focused licensing agreement with Laurus Labs. The developments extend its antibody-drug conjugate platform commercially, but clinical efficacy and the value of the new licensing arrangement remain undisclosed.
Medical Devices & Diagnostics
Blackstone and Boston Scientific strike $455m VITALYST deal targeting cardiogenic shock treatment by 2030
Blackstone Life Sciences has agreed to co-fund development of Boston Scientific's VITALYST temporary heart pump through a $455 million collaboration. The investment supports a strategic shift towards heart-attack-related cardiogenic shock, where established mechanical support technology has demonstrated survival benefits but significant safety risks remain.
Pharma & Biotech
Mirum Pharmaceuticals prepares new brelovitug, volixibat and LIVMARLI data for AASLD 2026
Mirum Pharmaceuticals will present additional evidence across three rare liver disease programmes at The Liver Meeting 2026. Already disclosed results include significant responses in the brelovitug AZURE-1 trial and volixibat VISTAS study, while longer-term and subgroup analyses may clarify safety, symptom improvement and regulatory prospects.
Pharma & Biotech
Gilead’s weekly HIV pill has passed Phase 3, but can fewer doses deliver better treatment adherence?
Gilead Sciences will present research spanning HIV prevention, treatment and early cure strategies at HIV Glasgow 2026. The programme includes new analyses of an already successful once-weekly Phase 3 regimen, real-world treatment evidence and investigations into twice-yearly injections, with several important regulatory and clinical questions still unresolved.
Medical Devices & Diagnostics
HeartBeam 3D ECG achieves 81.8% specificity in 132-patient heart attack study, beating standard ECG on one measure
HeartBeam has reported higher specificity and comparable sensitivity to a standard 12-lead ECG in a 132-patient acute coronary syndrome pilot. However, the recordings were made under clinical supervision, and the device's heart attack assessment function remains investigational ahead of a planned US pivotal study.